EX-99.1 2 d816002dex991.htm EX-99.1 EX-99.1

Slide 1

AVEO Overview November 2019

Slide 2

Cautionary Note Regarding Forward-Looking Statements

Slide 3

Slide 4

Multiple Potential Opportunities for Value Creation

Slide 5

Financial Highlights

Slide 6

FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

Slide 7

Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

Slide 8

TIVO-3: Study Design

Slide 9

TIVO-3: Superior PFS and ORR*

Slide 10

Progression-Free Survival – Key Subgroups*

Slide 11

Durable Disease Control with Tivozanib (Patients with > 1 year PFS)

Slide 12

Secondary Endpoint – Overall Survival

Slide 13

Pre-NDA Regulatory Feedback and POA

Slide 14

As OS Data Matures HR Improves

Slide 15

Treatment-Related Adverse Events* (≥20% frequency in either arm)

Slide 16

Slide 17

TIVO-3 Conclusions

Slide 18

PD-1 Combination Opportunities

Slide 19

Tivozanib Properties May Provide Advantages in Combination with IO Therapy

Slide 20

Phase 2 Data Presented at ESMO in September 2019

Slide 21

ESMO 2019: Encouraging Safety Results

Slide 22

ESMO 2019: Encouraging Efficacy

Slide 23

Combination of PD-1 + VEGF TKIs: Promising Responses, All Phase 3 Currently 1st Line

Slide 24

TiNivo – Strong Efficacy Seen in Both Treatment Naive and Previously Treated Patients

Slide 25

Immuno-Oncology Clinical Collaboration with AstraZeneca

Slide 26

Tivozanib Commercial Opportunity

Slide 27

If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States

Slide 28

Potential Relevance of Tivozanib in Refractory RCC

Slide 29

FOTIVDA® Commercialization in EU and ROW

Slide 30

Pipeline and Near-Term Milestones

Slide 31

Slide 32

Slide 33

Slide 34

Slide 35

AVEO Key Near Term Potential Milestones

Slide 36

AVEO Overview November 2019